Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Intravitreal Avastin for choroidal neovascularisation in pathological myopia: the controversy continues.

× No keyword cloud information.

40 in total

1. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.

Authors: Philip J Rosenfeld; Andrew A Moshfeghi; Carmen A Puliafito
Journal: Ophthalmic Surg Lasers Imaging Date: 2005 Jul-Aug

2. Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia.

Authors: Q D Nguyen; S Shah; S Tatlipinar; D V Do; E V Anden; P A Campochiaro
Journal: Br J Ophthalmol Date: 2005-10 Impact factor: 4.638

Review 3. Choroidal neovascularisation in pathological myopia: an update in management.

Authors: W-M Chan; M Ohji; T Y Y Lai; D T L Liu; Y Tano; D S C Lam
Journal: Br J Ophthalmol Date: 2005-11 Impact factor: 4.638

4. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment.

Authors: Robert L Avery
Journal: Retina Date: 2006-03 Impact factor: 4.256

5. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin).

Authors: Jonathan Shahar; Robert L Avery; Gad Heilweil; Adiel Barak; Esther Zemel; Geoffrey P Lewis; Patrick T Johnson; Steven K Fisher; Ido Perlman; Anat Loewenstein
Journal: Retina Date: 2006-03 Impact factor: 4.256

6. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment.

Authors: Raj K Maturi; Laura A Bleau; Donald L Wilson
Journal: Retina Date: 2006-03 Impact factor: 4.256

7. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study.

Authors: Diana Iturralde; Richard F Spaide; Catherine B Meyerle; Jay M Klancnik; Lawrence A Yannuzzi; Yale L Fisher; John Sorenson; Jason S Slakter; K Bailey Freund; Michael Cooney; Howard F Fine
Journal: Retina Date: 2006-03 Impact factor: 4.256

8. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage.

Authors: Richard F Spaide; Yale L Fisher
Journal: Retina Date: 2006-03 Impact factor: 4.256

9. Testing intravitreal toxicity of bevacizumab (Avastin).

Authors: Roberta P A Manzano; Gholam A Peyman; Palwasha Khan; Muhamet Kivilcim
Journal: Retina Date: 2006-03 Impact factor: 4.256

10. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study.

Authors: Stephan Michels; Philip J Rosenfeld; Carmen A Puliafito; Erin N Marcus; Anna S Venkatraman
Journal: Ophthalmology Date: 2005-06 Impact factor: 12.079

2 in total

1. Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization.

Authors: Lazaros Konstantinidis; Irmela Mantel; Jean-Antoine C Pournaras; Leonidas Zografos; Aude Ambresin
Journal: Graefes Arch Clin Exp Ophthalmol Date: 2008-11-29 Impact factor: 3.117

2. [Intravitreal bevacizumab for choroidal neovascularization due to pathological myopia].

Authors: S Dithmar; K B Schaal; A E Höh; S Schmidt; F Schütt
Journal: Ophthalmologe Date: 2009-06 Impact factor: 1.059

2 in total